Key points are not available for this paper at this time.
Orexin-A and -B (also known as hypocretin-1 and -2) are neuropeptides produced in the lateral hypothalamus that promote many aspects of arousal through the OX1 and OX2 receptors. In fact, they are necessary for normal wakefulness, as loss of the orexin-producing neurons causes narcolepsy in humans and rodents. This has generated considerable interest in developing small-molecule orexin receptor antagonists as a novel therapy for the treatment of insomnia. Orexin antagonists, especially those that block OX2 or both OX1 and OX2 receptors, clearly promote sleep in animals, and clinical results are encouraging: Several compounds are in Phase III trials. As the orexin system mainly promotes arousal, these new compounds will likely improve insomnia without incurring many of the side effects encountered with current medications.
Building similarity graph...
Analyzing shared references across papers
Loading...
Thomas E. Scammell
Christopher J. Winrow
The Annual Review of Pharmacology and Toxicology
Harvard University
Beth Israel Deaconess Medical Center
United States Military Academy
Building similarity graph...
Analyzing shared references across papers
Loading...
Scammell et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69ffd1834716aad0cc857af5 — DOI: https://doi.org/10.1146/annurev-pharmtox-010510-100528
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: